ArticleJournal of experimental & clinical cancer research : CR2022

Correction to: PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1/. BRCA1 DNA damage repair complex in prostate cancer cells.

Linglong Yin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.